Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
ConvaTec is a global medical products and technologies company specializing in advanced wound care, ostomy care, continence and critical care, and infusion devices. The company operates across 100+ countries with manufacturing facilities in the UK, US, Dominican Republic, and Mexico, serving both acute care hospitals and home healthcare markets. ConvaTec competes on clinical innovation in chronic condition management, particularly for aging populations with diabetes-related wounds, post-surgical ostomy needs, and urinary incontinence.
ConvaTec generates revenue through recurring consumable medical supplies sold via hospital contracts, long-term care facilities, and direct-to-consumer channels. The business benefits from high switching costs once clinicians adopt specific wound care protocols or ostomy patients establish product preferences. Gross margins of 56% reflect proprietary adhesive technologies, silicone formulations, and manufacturing scale advantages. The company captures value through clinical evidence demonstrating faster healing times and reduced infection rates, which justify premium pricing to hospital procurement departments focused on total cost of care rather than unit prices. Geographic diversification across US (40% revenue), Europe (35%), and emerging markets provides growth optionality.
Advanced Wound Care segment growth rates, particularly penetration of foam and antimicrobial dressings in US hospital systems and skilled nursing facilities
Ostomy Care market share gains versus Coloplast and Hollister, tracked through prescription data and patient loyalty metrics
Geographic revenue mix shifts, especially emerging market growth in China, India, and Latin America where aging populations drive chronic disease prevalence
New product launch success rates and regulatory approvals (FDA 510(k) clearances, CE marks) for next-generation wound care technologies
Operating margin expansion driven by manufacturing efficiency initiatives and shift toward higher-margin product categories
Healthcare reimbursement pressure as government payers globally implement cost containment measures, particularly CMS competitive bidding programs for durable medical equipment that could compress pricing 5-15% over multi-year periods
Technological disruption from advanced biologics and regenerative medicine approaches to wound healing that could commoditize traditional dressing products, though 5-10 year adoption timeline provides transition runway
Regulatory complexity with diverging standards across US FDA, European MDR requirements, and emerging market approvals creating 18-36 month product launch delays and compliance cost inflation
Market share erosion to larger diversified competitors (3M, Smith & Nephew, Mölnlycke) with broader product portfolios enabling bundled hospital contracts and cross-selling advantages
Private label and lower-cost generic wound care products gaining hospital formulary acceptance in cost-conscious European markets, particularly for commodity foam dressings
Direct-to-consumer channel disruption from e-commerce entrants and Amazon's healthcare expansion potentially disintermediating traditional ostomy care distribution relationships
Debt refinancing risk with £1.4B gross debt requiring management attention in rising rate environment, though 1.95x current ratio and £400M operating cash flow provide adequate coverage
Currency translation exposure with 60% of revenue outside UK reporting currency, particularly GBP/USD and GBP/EUR volatility creating 3-5% earnings variability
Pension obligations in UK legacy defined benefit schemes requiring ongoing funding contributions that could divert cash from growth investments
low - Medical device consumables for chronic conditions demonstrate recession-resistant demand characteristics. Wound care and ostomy products address non-discretionary medical needs driven by aging demographics, diabetes prevalence (10% of US population), and surgical procedures that continue regardless of economic conditions. However, elective surgery volumes can decline 10-15% during severe recessions, temporarily impacting ostomy product demand. Hospital capital equipment budgets face pressure during downturns, though ConvaTec's consumables focus provides insulation. Long-term care facility occupancy rates show modest GDP sensitivity.
Rising interest rates create moderate headwinds through two channels: (1) Higher financing costs on the company's £1.4B debt load (Debt/Equity 0.74), with estimated 50-75bps margin impact per 100bps rate increase assuming refinancing at current spreads; (2) Valuation multiple compression as healthcare growth stocks re-rate versus risk-free alternatives, particularly affecting the 12.8x EV/EBITDA multiple which sits at premium to diversified med-tech peers. However, the recurring revenue model and 4.3% FCF yield provide partial offset. Rate increases have minimal demand-side impact as healthcare spending decisions are clinically driven rather than financing-dependent.
Minimal direct credit exposure. Revenue is primarily from government payers (Medicare/Medicaid ~30%, European national health systems ~25%) and large hospital systems with strong credit profiles. Days sales outstanding typically 60-75 days with minimal bad debt historically. The company's own credit profile (estimated BB+/Ba1 range based on leverage metrics) affects refinancing costs but does not constrain operations. Tightening credit conditions could pressure smaller long-term care facility customers representing ~10% of revenue, but diversified payer mix mitigates concentration risk.
value - The stock appeals to investors seeking stable healthcare exposure with defensive characteristics, trading at reasonable valuation (2.6x P/S, 12.8x EV/EBITDA) relative to high-growth med-tech peers. The 4.3% FCF yield and improving profitability trajectory (46% net income growth) attract value-oriented healthcare specialists and dividend growth investors anticipating future payout initiation. Moderate 6.9% revenue growth and recurring revenue model suit investors prioritizing predictability over high-beta growth. Limited institutional ownership in US (ADR structure) creates potential re-rating opportunity if awareness increases.
low-to-moderate - Medical device stocks with consumables focus typically exhibit beta of 0.7-0.9 to broader markets. Recent performance (0.6% 1-year return, 3.6% 3-month return) demonstrates relative stability versus healthcare sector volatility. Stock moves primarily on earnings surprises, reimbursement policy changes, and M&A speculation rather than daily macro fluctuations. Currency volatility creates quarterly earnings variability but limited impact on long-term intrinsic value. Liquidity in US ADR market is moderate, potentially amplifying intraday moves on low volume.